Inicio
Fármacos Antitumorales
Colino quinasa como nueva diana terapeutica en cáncer.

8. Bibliografía


8.    Bibliografía

1.
Al-Saffar NM, Troy H, Ramírez de Molina A, Jackson LE, Madhu B, Griffiths JR, Leach MO, Workman P, Lacal JC, Judson IR, Chung YL. Noninvasive magnetic resonance spectroscopic pharmacodynamic markers of the choline kinase inhibitor MN58b in human carcinoma models. Cancer Res. 2006;66(1):427-434.
2.
Aoyama C, Liao H, Ishidate K. Structure and function of choline kinase isoforms in mammalian cells. Progress in Lipid Research 2004;43:266-281.
3.
Aznar S, Fernandez-Valeron P, Espina C, Lacal JC. Rho GTPases: potential candidates for anticancer therapy. Cancer Lett. 2004;206(2):181-191.
4.
Aznar S, Lacal JC. Rho signals to cell growth and apoptosis. Cancer Lett 2001;165:1-10.
5.
Bhakoo KK, Williams SR, Florian CL, Land H, Noble M. Immortalization and transformation are associated with specific alterations in choline metabolism. Cancer Res 1996;56:4630-4635.
6.
Borkenhagen LF,Kennedy EP. The enzymatic synthesis of cytidine diphosphate choline. J Biol Chem 1957;227:951-962.
7.
Burgering BMT, Coffer PJ. Protein kinase B (c-Akt) in phosphatidylinositol-3-OH kinase signal transduction. Nature 1995;376:599-602.
8.
Campos J, del Carmen Nunez M, Rodriguez V, Entrena A, Hernandez-Alcoceba R, Fernandez F, Lacal JC, Gallo MA, Espinosa A. LUMO energy of model compounds of bispyridinium compounds as an index for the inhibition of choline kinase. European Journal of Medicinal Chemistry 2001;36(3):215-225.
9.
Campos J, Nunez C, Diaz JJ, Sanchez RM, Gallo MA, Espinosa A. Anticancer bisquaternary heterocyclic compounds: a ras-ional design. Il Farmaco 2003;58(3):221-229.
10.
Campos J, Nunez MC, Conejo-Garcia A, Sanchez-Martin RM, Hernandez-Alcoceba R, Rodriguez-Gonzalez A, Lacal JC, Gallo MA, Espinosa A. QSAR-Derived Choline Kinase Inhibitors: How Rational can Antiproliferative Drug Design Be? Current Medicinal Chemistry 2003;10:1095-1112.
11.
Carnero A, Cuadrado A, del Peso L, Lacal JC. Activation of type D phospholipase by serum and ras-induced transformation in NIH3T3 cells. Oncogene 1994;9:1387-1395.
12.
Carnero A, Dolfi F, Lacal JC. Ras-p21 activates phospholipase D and A2, but no phospholipase C or PKC, in Xenopus laevis oocytes. J Cell Biochem 1994;54:478-486.
13.
Conejo-Garcia A, Banez-Coronel M, Sanchez-Martin RM, Rodriguez-Gonzalez A, Ramos A, Ramirez de Molina A, Espinosa A, Gallo MA, Campos JM, Lacal JC. Influence of the linker in bispyridium compounds on the inhibition of human choline kinase. J Med Chem. 2004;47(22):5433-5440.
14.
Conejo-Garcia A, Campos J, Sanchez RM, Rodriguez-Gonzalez A, Lacal JC, Gallo MA, Espinosa A. Choline kinase inhibitory effect and antiproliferative activity      of      new 1,1',1''-(benzene-1,3,5-triylmethylene)tris(1) tribromides. European Journal of Medicinal Chemistry 2003;38(1):109-116.
15.
Conejo-Garcia A, Campos JM, Sanchez-Martin RM, Gallo MA, Espinosa A. Bispyridinium Cyclophanes: Novel Templates for Human Choline Kinase Inhibitors. J Med Chem 2003;46(17):3754-3757.
16.
Cuadrado A, Carnero A, Dolfi F, Jiménez B, Lacal JC. Phosphorylcholine: a novel second messenger essential for mitogenic activity of growth factors. Oncogene 1993;8:2959-2968.
17.
Chung J, Grammer TC, Lemon KP, Kazlauskas A, Blenis J. PDGF- and insulin-dependent pp70S6k activation mediated by phosphatidylinositol-3-OH kinase. Nature 1994;370(6484):71-75.
18.
Chung T, Huang J-S, Mukherjee JJ, Crilly KS, Kiss Z. Expression of human choline kinase increases the mitogenic potential of insulin and insulin-like growth factor I. Cellular Signalling 2000;12:279-288.
19.
de Certaines JD, Larsen VA, Podo F, Carpinelli G, Briot O, Henriksen O. In vivo 31P MRS of experimental tumours. NMR Biomed 1993;6:345-365.
20.
del Peso L, Hernández R, Esteve P, Lacal JC. Activation of phospholipase D by Ras proteins in independent of Protein Kinase C. J Cell Biochem 1996;60:1-10.
21.
del Peso L, Lucas L, Esteve P, Lacal JC. Activation of phospholipase D by growth factors and oncogenes in murine fibroblasts follow alternative but cross-talking pathways. Biochem J 1997;322:519-528.
22.
Devary Y, Gottlieb RA, Smeal T, Karin M. The mammalian ultraviolet response is triggered by activation of Src tyrosine kinases. Cell 1992;71:1081-1091.
23.
Hernández-Alcoceba R, Fernández F, Lacal JC. In vivo antitumor activity of choline kinase inhibitors: a novel target for anticancer drug discovery. Cancer Research 1999;59:3112-3118.
24.
Hernández-Alcoceba R, Saniger L, Campos J, Nuñez MC, Khaless F, Gallo MA, Espinosa A, Lacal JC. Choline kinase inhibitors as a novel approach for antiproliferative drug design. Oncogene 1997;15:2289-2301.
25.
Hundertmark S, Lorenz U, Weitzel HK, Ragosch V. Effect of epidermal growth factor on enzymes of phospholipid buisynthesis in lung and liver of fetal rat in vivo and in vitro. Horm Metab Res 1999;31(1):8-13.
26.
Ishidate K, Tsuruoka M, Nakazawa Y. Induction of choline kinase by polycyclic aromatic hydrocarbon carcinogens in rat liver Biochem Biophys Res Commun 1980;96:946-952.
27.
Jimenez B, del Peso L, Montaner S, Esteve P, Lacal JC. Generation of phosphorylcholine as an essential event in the activation of Raf-1 and MAP-kinases in growth factors/induced mitogenic stimulation. J cell Biochem 1995;57:141-149.
28.
Kennedy EP, Weiss SB. The function of cytidine coenzymes in the biosynthesis of phospholipids. J Biol Chem 1956;222:193-214.
29.
Kim K-H, Carman GM. Phosphorylation and regulation of choline kinase from Saccharomyces cerevisiae by protein kinase A. J Biol Chem 1999;274:9531-9538.
30.
Kim KH, Voelker DR, Flocco MT, Carman GM. Expression, purification and characterization of choline kinase, product of the CKI gene from Saccharomyces cerevisiae. J Biol Chem 1998;273(12):6844-6852.
31.
Kiss Z, Chung T. Choline phosphatase and phosbol esters potentiate the mitogenic effect of insulin by competitive mechanism in NIH3T3 cells. Biochem Biophys Res Commun 1996;218:505-509.
32.
Kiss Z, Tomono M. Wortmannin inhibits carcinogen-stimulated phosphorylation of ethanolamine and choline. FEBS Lett 1995;358:243-246.
33.
Ko KW, Cook HW, Vance DE. Reduction of phosphatidylcholine turnover in a Nb 2 lymphona cell line after prolactin treatment. A novel mechanism for control of phosphatidylcholine levels in cells. J Biol Chem 1986;261(17):7846-7852.
34.
Lacal JC, Moscat J, Aaronson SA. Novel source of 1,2-diacylglicerol elevated in cells transformed by Ha-ras oncogene. Nature (Lond) 1987;33:269-271.
35.
Lacal JC. Choline kinase: a novel target for antitumor drugs. IDrugs 2001;4(4):419-426.
36.
Lacal JC. Diacylglycerol production in Xenopus laevis oocytes after microinjection of p21ras proteins is a consequence of activation of phosphatidylcholine metabolism. Mol Cell Biol 1990;10:333-340.
37.
Liu D, Hutchinsos OC, Osman S, Price P, Workman P, Aboagye EO. Use of radiolabelled choline as a pharmacodynamic marker for the signal transduction inhibitor geldanamycin. Brit J Cancer 2002;87:783-789.
38.
Malumbres M, Pellicer A. RAS pathways to cell cycle control and cell transformation. Front Biosci. 1998;3:d887-912. (Review)
39.
Man AS, Lee E, Choy PC. Biphasic modulation of choline uptake and phosphatidylcholine biosynthesis by vasopressin in rat cardiac myocytes. Lipids 1994;29(1):15-19.
40.
McMaster CR, Bell RM. Phosphatidylcholine biosynthesis via the CDP-choline pathwayt in Saccharomyces cerevisiae. Multiple mechanisms of regulation. J Biol Chem 1994;269(20):14776-14783.
41.
Millington WR, Wurtman RJ. Choline administration elevates brain phosphorylcholine concentrations. J Neurochem 1982;38(6):1748-1752.
42.
Monks DE, Goode JH, Dewey RE. Characterization of soybean choline kinase cDNAs and their expression in yeast and Escherichia coli. Plant Physiol 1996;110(4):1197-1205.
43.
Rodríguez-González A, Ramírez de Molina A, Fernández F and Lacal JC. Choline kinase inhibition induces the increase in ceramides resulting in a highly specific and selective cytotoxic antitumoral strategy as a potential mechanism of actionOncogene. 2004;23(50):8247-8259.
44.
Paddon HB, Vigo C, Vance DE. Diethylstilbestrol treatment increases the amount of choline kinase in rooster liver. Biochim Biophys Acta 1982;710(1):112-115.
45.
Pelech SL, Vance DE. Regulation of phosphatidylcholine biosynthesis. Biochem Biophys Acta 1984;779:217-251.
46.
Porter Tj, Kent C. Purification and characterization of choline/ethanolamine kinase from rat liver. J Biol Chem 1990;265(1):414-422.
47.
Radler-Pohl A, Sachesenmaier C, Gebel S, Auer H-P, Bruder JT, Rapp U, Angel P, Rahmsdorf HJ, Herrlich P. UV-induced activation of AP-1 involves obligatory extranuclear steps including Raf-1 kinase. Embo J 1993;12:1005-1012.
48.
Ramírez de Molina A, Banez-Coronel M, Gutierrez R, Rodríguez-González A, Olmeda D, Megias D, Lacal JC. Choline kinase activation is a critical requirement for the proliferation of primary human mammary epithelial cells and breast tumor progression. Cancer Res. 2004;64(18):6732-6739.
49.
Ramírez de Molina A, Gallego-Ortega D, Sarmentero J, Banez-Coronel M, Martin-Cantalejo Y, Lacal JC. Choline kinase is a novel oncogene that potentiates RhoA-induced carcinogenesis. Cancer Res. 2005;65(13):5647-5653.
50.
Ramírez de Molina A, Gutierrez R, Ramos MA, Silva JM, Silva J, Bonilla F, Sánchez JJ, Lacal JC. Increased choline kinase activity in human breast carcinomas: clinical evidence for a potential novel antitumor strategy. Oncogene. 2002;21(27):4317-4322.
51.
Ramírez de Molina A, Penalva V, Lucas L, Lacal JC. Regulation of choline kinase activity by Ras proteins involves Ral-GDS and PI3K. Oncogene. 2002;21(6):937-946.
52.
Ramírez de Molina A, Rodriguez-Gonzalez A, Gutierrez R, Martinez-Pineiro L, Sanchez JJ, Bonilla F, Rosell R, Lacal J. Overexpression of choline kinase is a frequent feature in human tumor-derived cell lines and in lung, prostate, and colorectal human cancers. Biochem Biophys Res Commun 2002;296:580-583.
53.
Ramírez de Molina A, Rodríguez-González A, Lacal JC. From Ras signalling to ChoK inhibitors: a further advance in anticancer drug design. Cancer Lett 2004 8;206(2):137-148. (Review).
54.
Ramírez de Molina A, Rodríguez-González A, Penalva V, Lucas L, Lacal JC. Inhibition of ChoK is an efficient antitumor strategy for Harvey-, Kirsten-, and N-ras-transformed cells. Biochemical and Biophysical Research Communications 2001;285:873-879.
55.
Ratnam S, Kent C. Early increase in choline kinase activity upon induction of the H-ras onocogene in mouse fibroblast cell lines. Arch Biochem Biophys 1995;323:313-322.
56.
Rodriguez-Gonzalez A, Ramirez de Molina A, Banez-Coronel M, Megias D, Lacal JC. Inhibition of choline kinase renders a highly selective cytotoxic effect in tumour cells through a mitochondrial independent mechanism. Int J Oncol 2005;26(4):999-1008.
57.
Rodriguez-Gonzalez A, Ramirez de Molina A, Fernandez F, Lacal JC. Choline kinase inhibition induces the increase in ceramides resulting in a highly specific and selective cytotoxic antitumoral strategy as a potential mechanism of action. Oncogene. 2004;23(50):8247-59.
58.
Rodriguez-Gonzalez A, Ramírez de Molina A, Fernandez F, Ramos MA, Nunez Mdel C, Campos J, Lacal JC. Inhibition of choline kinase as a specific cytotoxic strategy in oncogene-transformed cells. Oncogene 2003;22(55):8803-8812.
59.
Ruiz-Cabello J, Cohen JS. Phospholipid metabolitos as indicators of cancer cell function. NMR Biomed 1992;5:226-233.
60.
Sanchez-Martin R, Campos JM, Conejo-Garcia A, Cruz-Lopez O, Banez-Coronel M, Rodriguez-Gonzalez A, Gallo MA, Lacal JC, Espinosa A. Symmetrical Bis-Quinolinium Compounds: New Human Choline Kinase Inhibitors with Antiproliferative Activity against the HT-29 Cell Line. J Med Chem 2005;48(9):3354-3363.
61.
Smith TAD, Bush C, Jameson C, Titley JC, Leach MO, Filman DEV, McCready VR. Phospholipid metabolites, prognosis and proliferation in human breast carcinoma. NMR Biomed 1993;6:318-323.
62.
Tadokoro K, Ishidate K, Nakazawa Y. Evidence for the existence of isozymes of choline kinase and their selective induction in 3-methylcholanthrene- or carbon tetrachloride-treated rat liver. Biochim Biophys Acta. 1985;835(3):501-13.
63.
Teegarden D, Taparowsky EJ, Kent C. Altered phosphatidylcholine metabolism in C3H10T1/2 cells transfected with the Harvey-ras onocogene. J Biol Chem 1990;265:6042-6047.
64.
Uchida T, Yamashita S. Choline/ethanolamine kinase from rat brain. Methods Enzymol 1992;209:147-153.
65.
Uchida T. Immunologically and enzymatically distinct rat choline kinase isozymes. J Biochem 1994;116(6):1241-1250.
66.
Uchida T. Stimulation of phospholipid synthesis in HeLa cells by epidermal growth factor and insulin: activation of choline kinase and glycerophosphate acyltransferase. Biochim Ciophys Acta 1996;1304(2)89-104.
67.
Upreti RK. Influence of choline and ethanolamine administration on choline and ethanolamine phosphorylating activities of mouse liver and kidney. Can J Biochem 1979;57(7):981-985.
68.
Van Aelst L, D'Souza-Schorey C. Rho GTPases and signaling networks. Gen es Dev. 1997;11(18):2295-322. (Review)
69.
Vigo C, Paddon HB, Millard FC, Pritchard PH, Vance DE. Diethylstilbestrol treatment modulates the enzymatic activities of phosphatidylcholine biosynthesis in rooster. Biochim Biophys Acta 1981;665(3):546-550.
70.
Warden CH, Friedkin M. Regulation of choline kinase activity and phosphatidylcholine biosynthesis by mitogenic growth factors in 3T3 fibroblasts. J Biol Chem 1985;260:6006-6011.
71.
Wennerberg K, Der CJ. Rho-family GTPases: it's not only Rac and Rho (and I like it). J Cell Sci 2004;117:1301-1312.
72.
Wieprecht M, Wieder T, Geilen CC. N-[2-bromocinnamyl(amino)ethyl]-5-isoquinolinesul phonamide (H-89) inhibits incorporation of choline into phosphatidylcholine via inhibition of choline kinase and has no effect on the phosphorylation of CTP:phosphocholine cytidylyltransferase. Biochem J. 1994;297(Pt 1):241-247.
73.
Yu Y, Sreenivas A, Ostrander D, Carman GM. Phosphorylation of Saccharomyces cerevisiae Choline Kinase on Ser30 and Ser85 by Protein Kinase A Regulates Phosphatidylcholine Synthesis by the CDP-choline Pa t h way. J Biol Chem 2002;277(38):34978-34986.